Pharmafile Logo
Pharmafocus logo
Advanced Search

remdesivir

Showing 15 posts of 28 posts found.

Jubilant’s oral remdesivir formulation shows positive results in human trial

April 22, 2021
COVID-19, Gilead, Jubilant Pharma, covid-19 treatment, pharma, pharma news, remdesivir

Jubilant Pharma has announced the successful completion of studies in human volunteers for their oral formulation of remdesivir – an …

News
covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

November 4, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir

As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …

News
pharmafocus_november_2020_cover

The November 2020 issue of Pharmafocus is available to read free online now!

October 27, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Biden, Pharmafocus, Trump, UK, US election, brexit, pharma, remdesivir

The latest monthly edition of Pharmafocus is available to read for free online now!

News
fdaoutsideweb

FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients

October 23, 2020
Medical Communications, Sales and Marketing COVID-19, FDA, Gilead, remdesivir

The FDA has approved Gilead’s antiviral therapy Veklury (remdesivir) for the treatment of hospitalised COVID-19 patients, making it the first …

News
eu_member_flags

European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit

October 19, 2020
Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir

As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …

News
shutterstock

Gilead’s remdesivir and three other repurposed drugs have no impact on COVID-19 mortality, WHO study finds

October 16, 2020
Medical Communications, Research and Development COVID-19, pharma, remdesivir

Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections, but recent studies …

News
shutter

Remdesivir has a “favourable” benefit/risk profile in COVID-19 but more data needed, DSRU review argues

October 5, 2020
Research and Development, Sales and Marketing COVID-19, Drug Safety Research Unit, pharma, remdesivir

Southampton’s Drug Safety Research Unit (DSRU) has released a systematic benefit/risk analysis of Gilead’s antiviral drug remdesivir in the treatment …

News
lilly_building_with_american_flag_web

Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data

September 15, 2020
Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir

Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …

News
shutterstock_158366573

Racial minority groups are not adequately represented in COVID-19 clinical studies, research argues

August 12, 2020
Research and Development COVID-19, Gilead, pharma, remdesivir

New research has warned that minority groups and people of colour are underrepresented in current trials for COVID-19 therapies, despite …

News
mylan_building

Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India

July 20, 2020
Sales and Marketing COVID-19, Gilead, India, Mylan, generic, remdesivir

Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with …

News
shutterstock_159488225

New data shows Gilead’s remdesivir “potently inhibited” SARS-CoV-2 in human lung cell cultures

July 10, 2020
Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir

New findings published from researchers at Vanderbilt University Medical Center (VUMC) at the University of North Carolina, as well as …

News
remdesivir_ulrich_perrey

Gilead’s remdesivir becomes first EU-recommended therapy for COVID-19

June 26, 2020
Medical Communications, Sales and Marketing COVID-19, EU Gilead, remdesivir

In a crucial step amidst the ongoing pandemic, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) …

News
gilead-sciences

Gilead to investigate inhaled formulation of promising COVID-19 therapy remdesivir

June 23, 2020
Manufacturing and Production, Research and Development COVID-19, Gilead, remdesivir

Gilead is intent on pushing the applications of its antiviral drug remdesivir after it has shown efficacy in the treatment …

News
remdesivir_ulrich_perrey

EMA could approve Gilead’s streamlined remdesivir application for COVID-19 “within weeks”

June 9, 2020
Manufacturing and Production, Sales and Marketing COVID-19, EU, Gilead, coronavirus, remdesivir

The European Medicines Agency has received the application from Gilead for the first conditional marketing authorisation (CMA) of its antiviral …

News
remdesivir_ulrich_perrey

Australian Taskforce recommends Gilead’s remdesivir for routine use in the country’s COVID-19 patients

June 5, 2020
Medical Communications, Sales and Marketing Australia, COVID-19, Gilead, coronavirus, remdesivir

Australia could be set to follow the decisions of other nations around the world in officially licensing Gilead’s antiviral therapy …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023